Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 360
- Registration Number
- NCT05035277
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴Oslo Univesity Hospital - Ullevål, Oslo, Norway
🇳🇴Oslo University Hospital - Rikshospitalet, Oslo, Norway
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55759
- Registration Number
- NCT05022563
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷Sungkyunkwan University, Suwon-si, Korea, Republic of
DOT HeartMate 3 Study
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Institute for Clinical and Experimental Medicine
- Target Recruit Count
- 45
- Registration Number
- NCT04974684
- Locations
- 🇨🇿
Institute for Clinical and Experimental Medicine, Prague, Czechia
Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- University of Texas at Austin
- Target Recruit Count
- 100
- Registration Number
- NCT04891861
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 1000000
- Registration Number
- NCT04878497
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
- Conditions
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Palak Shah
- Target Recruit Count
- 30
- Registration Number
- NCT04865978
- Locations
- 🇺🇸
Inova Fairfax Medical Campus, Falls Church, Virginia, United States
Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 80
- Registration Number
- NCT04850378
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 14914
- Registration Number
- NCT04818151
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04809818
- Locations
- 🇺🇸
Lumosa Phase 1 Unit, Cypress, California, United States
NOAC Portuguese Real World Study
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04808934
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.